Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism

被引:91
作者
Soyama, A
Saito, Y
Hanioka, N
Murayama, N
Nakajima, O
Katori, N
Ishida, S
Sai, K
Ozawa, S
Sawada, J
机构
[1] Natl Inst Hlth Sci, Project Team Pharmacogenet, Setagaya Ku, Tokyo 1588501, Japan
[2] Natl Inst Hlth Sci, Div Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan
[3] Natl Inst Hlth Sci, Div Environm Chem, Setagaya Ku, Tokyo 1588501, Japan
[4] Natl Inst Hlth Sci, Div Drug, Setagaya Ku, Tokyo 1588501, Japan
[5] Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan
[6] Natl Inst Hlth Sci, Div Xenobiot Metab & Disposit, Setagaya Ku, Tokyo 1588501, Japan
关键词
CYP2CS; polymorphism; paclitaxel; metabolism;
D O I
10.1248/bpb.24.1427
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
By sequencing genomic DNA from 73 established cell lines derived from Japanese individuals, we detected 9 single nucleotide polymorphisms (SNPs) in the CYP2C8 gene. Of them, 3 exonic SNPs resulted in amino acid alterations (g416a, R139K; a1196g, K399R; c1210g, P404A). The first two alterations were detected concurrently in one cell line and thought to be the same as CYP2C8*3. To examine the effects of these amino acid alterations on CYP2C8 function, wild-type and four types of variant CYP2C8 cDNA constructs (R139K, K399R, R139K/K399R and P404A) were transfected into Hep G2 cells and their paclitaxel 6 alpha -hydroxylase activities were determined in vitro. K-m values were not significantly different from that of the wild-type in any of the variants studied. The variant R139K/K399R showed reduced values for V-max and clearance (V-max/K-m) similar to those of its single variant, R139K. The variant P404A also showed a significantly lowered clearance due to reduced level of protein expression. These results suggest that not only the double variant (R139K/K399R, CYP2C8*3) but also our novel variant P404A in the CYP2C8 gene are less efficient in paclitaxel metabolism.
引用
收藏
页码:1427 / 1430
页数:4
相关论文
共 19 条
  • [1] Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424
  • [2] BROWN T, 1997, CURRENT PROTOCOLS S, V37
  • [3] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [4] Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
    Ingelman-Sundberg, M
    Oscarson, M
    McLellan, RA
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) : 342 - 349
  • [5] FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS OF CHROMOSOMAL LOCALIZATION OF 3 HUMAN CYTOCHROME-P450-2C GENES (CYP2C8, 2C9, AND 2C10) AT 10Q24.1
    INOUE, K
    INAZAWA, J
    SUZUKI, Y
    SHIMADA, T
    YAMAZAKI, H
    GUENGERICH, FP
    ABE, T
    [J]. JAPANESE JOURNAL OF HUMAN GENETICS, 1994, 39 (03): : 337 - 343
  • [6] JOHANSSON I, 1994, MOL PHARMACOL, V46, P452
  • [7] HUMAN LIVER CARBAMAZEPINE METABOLISM - ROLE OF CYP3A4 AND CYP2C8 IN 10,11-EPOXIDE FORMATION
    KERR, BM
    THUMMEL, KE
    WURDEN, CJ
    KLEIN, SM
    KROETZ, DL
    GONZALEZ, FJ
    LEVY, RH
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (11) : 1969 - 1979
  • [8] Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO
  • [9] 2-N
  • [10] Mück W, 2000, CLIN PHARMACOKINET, V39, P99